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Strengths and limitations of this study
 ► This study will provide evidence regarding the 
non-specific effects of BCG and oral polio vaccine 
(OPV) provided at birth.
 ► The trial will be the first randomised trial to as-
sess non-specific effects of BCG and OPV in a rural 
low-income setting.
 ► The trial tests a feasible add-on intervention to the 
currently WHO-recommended home visits.
 ► The study will provide a cost-effectiveness analysis 
of providing BCG and OPV at a single home visit after 
birth.
 ► The trial tests co-administering BCG and OPV at 
birth and will not be able to conclude on separate 
non-specific effects of the individual vaccines.
AbStrACt
Introduction The BCG vaccine is designed to protect 
against tuberculosis, but the vaccine may have broader 
effects. In 2014, the Strategic Advisory Group of Experts 
on Immunization reviewed the literature on non-specific 
effects of BCG, and concluded that the evidence was 
consistent with beneficial non-specific effects and 
requested further randomised trials.
Methods and analyses Within the Bandim Health 
Project’s urban and rural health and demographic 
surveillance systems, we will conduct a cluster-
randomised trial in six suburban districts and 55 rural 
villages. Infants are enrolled at a home visit before 
72 hours of life. In intervention clusters, children are 
vaccinated with BCG and oral polio vaccine (OPV). In 
control clusters, the caregivers are informed about 
vaccination opportunities. Using Cox-proportional hazards 
models, we will test whether BCG and OPV provided at a 
single home visit can reduce early infant mortality up to 
60 days.
The trial was initiated with a pilot study in Biombo 
region in June 2015. The trial was scaled up to full study 
including Oio and Cacheu regions in July 2016. The trial 
was expanded to include the urban study area in July 
2017.
Ethics and dissemination BCG vaccination is delayed 
in many low-income settings. WHO-recommended home 
visits are resource demanding and vaccines are not 
part of the recommendation. Utilising the home visits to 
provide BCG and OPV may provide countries with a further 
incentive to introduce a single home visit. In countries, 
where home visits are already in place, vaccines can 
easily be added to reduce early infant mortality. The trial 
is approved by the Guinean Ethical Committee (Reference 
number: 0016/CNES/INASA/2015) and the Danish Ethics 
Committee has given its consultative approval. The results 
of the trial will be published in international peer-reviewed 
journals.
trial registration number NCT02504203; Pre-results.
IntroduCtIon
WHO recommends home visits after birth to 
reduce neonatal mortality.1 2 Guinea-Bissau 
has not implemented such home visits yet. 
Vaccinations are not an integrated part of 
home visits and are normally provided at 
the health centres. The current vaccination 
policy is to provide BCG vaccine and oral 
polio vaccine (OPV) at birth (vaccination 
schedule, figure 1).
Public health policies in low-income coun-
tries are based on a one-disease-one-solution 
paradigm: for each of the important diseases, 
a specific vaccine is developed. It is believed 
that the vaccine prevents only the specific 
disease and does nothing else. Therefore, 
most routine vaccines have not been tested 
for their effect on overall mortality.
However, many observational studies3–5 
and randomised controlled trials (RCTs)6–9 
in low-income countries have now shown that 
apart from preventing specific diseases, the 
vaccines may also have wider effects on the 
immune system, which leads to changes in resis-
tance/susceptibility to unrelated infections.10
With respect to BCG, observational studies 
show that BCG is associated with better child 
survival,3 11 12 which cannot be explained by 
prevention of tuberculosis (TB).13 WHO recom-
mends BCG vaccine at birth in low-income 
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Figure 1 Recommended vaccination schedule in Guinea-
Bissau.
countries. Typically low-weight (LW) children (<2500 g) are 
only vaccinated when they reach 2500 g. These children are 
assumed to be immunologically immature, and BCG vacci-
nation is therefore often delayed. However, in three RCTs 
in Guinea-Bissau, BCG-at-birth reduced neonatal mortality 
in LW children, the combined analysis showed a mortality 
reduction of 38% (95% CI: 17% to 54%).6 7 TB is very rare 
in early childhood14 and the effects can therefore not be 
ascribed to prevention of TB. The effect of BCG-at-birth 
on neonatal mortality was seen already during the first 3 
days post-vaccination, the reduction in mortality being 45% 
(7%–68%).9 This rapid effect suggests that the effect is due 
to changes in the innate immune system.
Recent immunological studies support that BCG induces 
epigenetic changes in monocytes, which reprogram the 
innate immune system to increased pro-inflammatory 
responses against unrelated pathogens.15 16 These find-
ings thus provide biological mechanisms whereby BCG 
could exert non-specific beneficial effects, protecting the 
recipients against non-targeted infectious diseases.16 17
Approximately 75% of neonatal deaths occur within the 
first week of life,13 but BCG is rarely given at birth in low-in-
come countries; only 11% of the children receive BCG in 
the first week of life in Guinea-Bissau.18 A major reason 
for this delay is the focus on reducing wastage of vaccines. 
Freeze-dried vaccines like BCG have to be used within 6 
hours after reconstitution with a diluent. Therefore, a vial 
of BCG vaccine is often not opened unless 10–12 children 
are present for vaccination. Hence, there are many missed 
vaccination opportunities. If BCG vaccine has profound 
effects on neonatal mortality and morbidity many lives 
could be saved by providing BCG earlier.
In this study, we aim to study the effect of BCG and OPV 
vaccinations provided at a single home visit within 72 
hours after birth on early infant mortality and morbidity 
among infants in a rural and an urban setting in Guin-
ea-Bissau. We hypothesise that BCG and OPV at birth 
provided at a single home visit shortly after birth reduce 
early infant non-accidental mortality by 40%.
MEthodS And AnAlySES
Setting
The study is conducted in Bandim Health Project’s (BHP) 
health and demographic surveillance system (HDSS) sites 
in rural and urban Guinea-Bissau.
Rural site
The rural HDSS was established in 1990. The BHP teams 
survey women of fertile age and their children below the 
age of 5 years in randomly selected clusters of villages in 
all the nine health regions in the country. Children in the 
three rural regions closest to Bissau (Oio, Biombo and 
Cacheu) are eligible for the study.
The rural clusters are followed with two monthly 
visits by the mobile teams. At all visits, the women are 
asked whether they are pregnant. When a pregnancy 
is registered, the woman’s nutritional status is assessed 
by measurement of a mid-upper-arm-circumference 
(MUAC); information on antenatal care is collected prior 
to giving birth, as well as at the first visit after delivery. 
Socioeconomic factors (type of roofing, type of bathroom, 
possession of a mobile phone, radio and generator) are 
registered. After the delivery, information on the place 
of delivery (home, health facility) and who assisted the 
delivery is collected.
Urban site
The urban HDSS was established in 1978. Field assistants 
follow children below the age of 3 years through home 
visits every third month. Pregnancies are registered every 
month and followed monthly until birth. When a preg-
nancy is registered information on ethnic group, gesta-
tional age, use of mosquito net is collected. After the 
delivery, information on place of delivery (home, health 
facility) is collected. All children in the urban study area 
will be eligible for the study.
Study nurses
Prior to study start, we selected study nurses to conduct 
home visits. In the rural study area, study nurses were 
selected in collaboration with the regional health author-
ities. The nurses were selected among nurses working at a 
health centre with a catchment area corresponding to the 
study clusters, so the home visits can be done in addition 
to their normal routines. For the urban study area, the 
BHP employed a study nurse fulltime.
Community key informants
In the rural areas, to ensure that the nurses are informed 
immediately about deliveries, we use community key 
informants (CKIs). CKIs were selected among residents in 
each rural village to collect information about pregnan-
cies, deliveries and deaths. The CKI communicate imme-
diately any delivery in the village to the study nurse. In the 
urban area, we take advantage of the close follow-up by 
the field assistants, who circulate the zones daily.
Study design and randomisation
The trial is a cluster-randomised trial, randomising clus-
ters (village clusters/sub-district zones) to two different 
treatment groups, stratified by region and pre-trial 
mortality level (high/low).
Clusters, defined as village cluster in the rural area, and 
as sub-district zones in the urban area, were randomised 
prior to study start using computer-generated random 
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Table 1 Trial design
Timing
Routine visit 
before birth Shortly after birth—within 72 hours
First routine visit after 
birth
Second and third 
routine visit after birth
Personnel BHP field assistant 
and nurse
CKI Study nurse BHP field assistant 
and nurse
BHP field assistant 
and nurse
Control group Information about 
trial and invitation 
to participate. 
Informed consent.
CKI inform about 
birth
 ► Umbilical cord and 
skin care
 ► Encourage skin-to-
skin contact to keep 
the newborn warm
 ► Examine and weigh 
the child
 ► Inform about 
vaccination 
opportunities
Field assistant:
 ► Interview on 
morbidity and 
mortality
Nurse:
 ► Examine the BCG 
vaccination site 
and lymph glands
 ► Measure 
temperature
 ► Weigh the child
 ► Provide BCG and 
OPV
Field assistant:
 ► Interview on 
morbidity and 
mortality
Nurse:
 ► Examine the BCG 
vaccination site 
and lymph glands
 ► Measure 
temperature
 ► Weigh the child
 ► Provide routine 
vaccinations
Intervention 
group
 ► Umbilical cord and 
skin care
 ► Encourage skin-to-
skin contact to keep 
the newborn warm
 ► Examine and weigh 
the child
 ► Provide BCG and 
OPV
Field assistant:
 ► Interview on 
morbidity and 
mortality
Nurse:
 ► Examine the BCG 
vaccination site 
and lymph glands
 ► Measure 
temperature
 ► Weigh the child
Bold and italics stress the differences between the intervention and control groups.
BHP, Bandim Health Project; CKI, community key informant; OPV, oral polio vaccine.
numbers. All newborns are visited as soon as possible 
after birth. In half of the clusters, we provide standard 
care and vaccines (BCG, OPV) to children at the home 
visits; in the remaining clusters, children only receive 
standard care but no vaccines (table 1). The trial is 
unblinded.
Inclusion criteria
All children registered during pregnancy are eligible for 
the study. Children can only be enrolled if they are visited 
within 72 hours after birth.
Exclusion criteria
There are few exclusion criteria, because the study is 
expected to answer a pragmatic question about the effect 
of BCG and OPV vaccination at home visits shortly after 
birth.
 ► Children already BCG vaccinated.
 ► Moribund children (expected not to survive the next 
24 hours, as evaluated by the study nurse at the enrol-
ment visit).
 ► Children in rural villages where the BHP mobile 
teams coincidentally were in the village the same day 
(and vaccinated all children).
Informed consent
All pregnant women receive an oral and a written expla-
nation of the study, and are offered to participate in the 
study at the time of registration of the pregnancy. In the 
rural area, the explanation is given by the BHP nurse at 
the two monthly visits. In the urban area, the explanation 
is given by the fieldwork assistant at a monthly visit. It is 
explained that normally newborn children receive their 
first vaccinations at the health centres. However, studies 
have suggested that it might be beneficial to receive 
BCG and OPV early and the BHP will therefore test the 
effect of providing the vaccines at home visits. All chil-
dren receive a home visit with standard care. Children in 
half the clusters (intervention clusters) receive BCG and 
OPV at enrolment. Children in the control clusters can 
seek vaccination elsewhere and will be offered the BCG 
vaccine and OPV at the next home visit by the BHP team 
if they did not get it elsewhere. If the pregnant woman 
accepts to take part in the study, they are asked to sign 
or fingerprint a consent form. An independent witness 
confirms the consent process by co-signing the form.
Enrolment
The study nurse visits every newborn child shortly after 
a CKI/mother calls, if possible on the same day. At the 
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home visit, the nurse asks the mother for confirmation 
of her consent for participation in the study before 
revealing the randomisation. If the mother is not able to 
present the signed consent form, new consent forms are 
filled in. The nurse brings a questionnaire, a sticker with 
study number and a vaccination card.
Intervention
For all children, the nurse examines and weighs the child, 
encourages skin-to-skin contact to keep the newborn 
warm and if necessary performs umbilical cord care.1 
Following interview and examination, group allocation is 
disclosed to the mother. For children in the control clus-
ters, the nurse informs about vaccination opportunities 
(vaccination at closest health centre or vaccination by 
BHP nurse at next visit), as recommended by WHO.1 For 
children in the intervention clusters, the nurse adminis-
ters BCG and OPV (table 1).
BCG vaccine
BCG vaccination is administered by intradermal injec-
tion; after vaccination most children develop a scar at the 
injection site. Among BCG-vaccinated children, having 
a BCG scar is associated with improved survival.19–21 
The proportion of children developing a scar after BCG 
vaccination depends on the vaccination technique and 
strain.22–24 All nurses have been trained prior to the trial 
and supervised intensively during the beginning of the 
trial to ensure correct vaccination technique. The Tokyo 
172 BCG strain from BCG Japan is used for the study. The 
vaccine is prequalified by WHO and is regularly used in 
the national vaccination programme in Guinea-Bissau.
OPV vaccine
The OPV vaccine is supplied from the national vaccina-
tion programme and thus strain, manufacturer and batch 
may vary. For all vaccines, the manufacturer, batch and 
expiration date are registered.
Follow-up
All children enrolled in the study receive two follow-up 
visits. At follow-up visits, the child is weighed, and the 
BHP nurse examines lymphadenopathy and reaction at 
the vaccination site.
Follow-up in the rural regions
The study participants are followed through the rural 
HDSS, where all children below 5 years of age are 
followed, and information on vital status, breastfeeding 
status, supplementary feeding, MUAC, vaccinations, 
hospital admissions and whether the child has received 
interventions provided in campaigns is collected.
The BHP teams are accompanied by a nurse, who 
administers vaccines. The BHP nurse performs the 
follow-up visits for this study. All children have their vacci-
nation cards examined and those missing one or more 
routine vaccines according to the schedule are offered 
these vaccines at the follow-up visits.
Follow-up in the urban region
The study participants receive two follow-up visits by the 
study nurse at 2 and 4 months of age. The study nurse 
brings BCG and OPV for children in control clusters. For 
the remaining routine vaccines as part of the national 
programme, the children are referred to the closest 
health centre. All children below the age of 3 years are 
followed through home visits every third month, where 
information on vital status, breastfeeding status, supple-
mentary feeding, MUAC, vaccinations, hospital admis-
sions and vaccination campaigns is collected.
Outcomes
The primary outcome is non-accidental mortality rate 
between enrolment visit or 24 hours after birth, which-
ever comes last, and 60 days of life. Follow-up time will 
be censored at the first of visit by the BHP, death due to 
accident, date of registration of first non-trial vaccine 
given after enrolment or migration. All children living in 
intervention and control clusters are followed through 
the HDSS routines with collection of information on vital 
status for all children. Deaths are classified as accidental 
or non-accidental based on information from verbal 
autopsies.
Secondary outcomes and potential effect modifiers
We will evaluate the effect on severe morbidity consid-
ered as the composite outcome of non-accidental death 
and non-accidental hospital admission. With declining 
mortality, we may not be able to obtain a conclusive result 
for the primary outcome. We have defined the sample 
size for the composite outcome, but retained mortality as 
the primary outcome.
We will conduct secondary analyses to assess whether an 
effect varies by low birth weight (<2500 g), sex, maternal 
BCG scarring and season to gain a better knowledge of 
the potential effect modifiers (a list of all outcomes can 
be found in box 1).
We will study the cost-effectiveness of providing BCG 
and OPV at a home visit using the effects on mortality and 
hospital admission from this project.
For all deaths a verbal autopsy will be made. These will 
mainly be used to classify a death as accidental or non-ac-
cidental, but where possible, we will also report cause-spe-
cific mortality.
Data management
All data are collected on paper forms and entered in 
the BHP office. Records with registration of all pregnant 
women are copied from the data tables of the routine 
HDSS to the BCG trial data table. Forms for follow-up 
are pre-printed with identification information of the 
enrolled children. For routine HDSS visits, a list of all 
pregnant women is printed prior to the visit to ensure 
that all pregnant women are invited to participate in the 
study prior to giving birth. Following data entry, the data 
are checked for consistency. Inconsistencies between the 
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box 1 outcomes
Primary outcome
 ► Early infant non-accidental mortality.*
Potential effect modifiers
 ► Low birth weight defined as birth weight lower than 2500 g.
 ► Sex.
 ► Maternal BCG scarring.
 ► Season.
Secondary outcomes
 ► Non-accidental hospital admission.*
 ► Severe morbidity (composite outcome of non-accidental mortality 
and non-accidental hospital admissions).*
 ► Consultations.†
 ► Growth.‡
Mid-upper-arm circumference.
Weight-for-age z-score.
 ► BCG scarring.†
 ► Cost-effectiveness of providing BCG and oral polio vaccine at home 
visits.
 ► Cause-specific mortality.
*Analysed using Cox proportional hazards models. Further details are provided 
in online supplementary appendix 2.
†Analysed using log-binomial regression. Further details are provided in online 
supplementary appendix 2.
‡Analysed using linear regression. Further details are provided in online 
supplementary appendix 2.
BCG trial data and the HDSS data are checked. Main 
outcome events are reviewed individually.
Statistical analyses
General analysis principles applied in all analyses can be 
found in online supplmentary appendix 1. In Cox-pro-
portional hazards models with age as underlying times-
cale, we will assess the effect of providing BCG and OPV 
at a single home visit. We will allow for different baseline 
hazards according to the factors used in the randomisation 
(region and pre-study mortality level) and sex. Children 
enter the analysis on the date of enrolment or 24 hours 
of age, whichever comes last, and remain in the analysis 
until the first subsequent visit by the BHP team, date of 
registering first non-trial vaccine after enrolment, death 
or migration within the first 60 days of life. In secondary 
analyses, we will investigate whether the effect of BCG 
+OPV differ by the following potential effect modifiers, 
which in prior trials have been important determinants 
of the effect: low birth weight (<2500 g), sex, maternal 
BCG scarring, and season. Further details are provided in 
online supplementary appendix 2.
Secondary outcomes are non-accidental hospital admis-
sions, severe morbidity (composite outcome of non-acci-
dental mortality and non-accidental hospital admissions), 
consultations, growth (MUAC and weight-for-age z-score) 
and BCG scarring. Analyses are described in online 
supplementary appendix 2. We will furthermore perform 
a cost-effectiveness analysis seeking to measure the cost 
per death averted using a societal perspective, contrasting 
the costs of vaccine provision in the present programme 
and an outreach system as tested in the trial. The final 
analysis plan is deposited with the Data Safety and Moni-
toring Board. A list of all planned analyses is provided in 
online supplementary appendix 2.
Sample size considerations
We estimated the design effect to 1.35 (ratio of square of 
the standard errors for the cluster-adjusted/unadjusted 
Hazard Ratios (HR)) based on pre-trial event data (deaths 
and hospitalisation) from the rural HDSS clusters, where 
the study is conducted. We base our sample size calcula-
tion on the combined secondary outcome for feasibility 
reasons, but retain mortality as the primary outcome. 
We estimated the proportion of events to be 2.4% in the 
absence of our intervention (prior data). Thus, in order 
to obtain 80% power to detect a reduction in early infant 
severe morbidity if the true reduction of BCG and OPV 
provided at home visits is larger than 40%, we will need 
to enrol at least 6666 children. This sample size has 74% 
power to detect a significant difference in mortality if the 
real effect is a 40% reduction from a mortality level of 
2.1%.
Time schedule
The trial was initiated with a pilot study in Biombo 
region in June 2015. The trial was scaled up to full study 
including Oio and Cacheu regions in July 2016. The trial 
was expanded to include the urban study area in July 
2017. In March 2019, the trial was stopped in the urban 
study area and in the Cacheu region, due to lower than 
anticipated number of enrolments and number of events, 
resulting in a lower than anticipated power. As a result 
of the lower than anticipated power, we plan to end the 
trial prematurely in Oio and Biombo health regions in 
September 2019. The results of the trial will be reported 
as planned despite the lower than anticipated power.
Ethics and dissemination
Ethical considerations
BCG is recommended at birth but vaccination is often 
delayed; in rural Guinea-Bissau most children receive 
BCG after 1 month.18 While there is now increasing 
acceptance that BCG may have beneficial non-specific 
effects, we are still a long way from altering the imple-
mentation of the vaccination programme. The proposal 
compares two ways of delivering BCG and OPV; both are 
an improvement relative to the current situation in rural 
Guinea-Bissau, where less than 40% of all infants get BCG 
during the first month of life.18 Hence, no child receives 
BCG later than it would have done, had the trial not been 
carried out. The trial is registered at  clinicaltrials. gov.
Safety monitoring
A data safety and monitoring board has been formed 
consisting of a paediatrician (Anja Poulsen, Rigshos-
pitalet, Denmark), a statistician (Morten Frydenberg, 
Aarhus University, Denmark) and an epidemiologist 
(Torben Sigsgaard, Aarhus University, Denmark). The 
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members have been appointed on their experience, 
reputation for objectivity, absence of conflicts of interest 
and knowledge on clinical trial methodology.
The vaccines used for the trial are prequalified by 
WHO to be given at birth. Adverse reactions are rare for 
both BCG and OPV. At the two first visits after enrolment 
in the study, the BHP nurse examines the BCG vaccina-
tion site and the axillary lymph glands of all children to 
assess suppurative lymphadenitis as an adverse reaction 
to the BCG vaccination. Other serious adverse events are 
captured through primary and/or secondary outcomes 
(mortality, hospitalisations and consultations).
dissemination
The results of the study will be published in interna-
tional peer-reviewed journals and results will be commu-
nicated to the National Institute of Public Health in 
Guinea-Bissau. After publication of the main results on 
completion of the trial, data requests can be submitted to 
the researchers at BHP.
The SPIRIT checklist can be found in the online supple-
mentary file 1.
Protocol amendments
Any protocol modifications will be discussed with the 
Data Safety and Monitoring Board, and changes will be 
added to the trial registration.
Patient and public involvement
The communities were involved in locating households, 
when the HDSS was setup and contributed information 
allowing tracing of internal migrants between villages 
throughout the study period. No participants were 
involved in setting the research question or the outcome 
measure, nor were they involved in developing plans for 
recruitment, design or implementation of the study. Local 
CKIs were selected to ensure timely information about 
birth. Nurses from local health centres are involved in the 
study and have been trained to perform enrolment. This 
ensures a close collaboration with the local health system. 
No participant was asked to advise on interpretation or 
writing up the results. The results are disseminated to 
the national public health institute. There are no plans 
to disseminate the results of the research to study partic-
ipants. Study results will be disseminated to local nurses 
involved in the study.
dISCuSSIon
WHO recommends BCG and OPV at birth. However, due 
to the focus on not wasting vaccine doses, BCG vaccination 
is often delayed.18 25–27 Previous trials from Guinea-Bissau 
have showed that early vaccination may have major impact 
on neonatal mortality among LW children,6 7 9 and observa-
tional studies have suggested that BCG also has beneficial 
non-specific effects(NSE) among normal-birth-weight chil-
dren.3 11 In 2014, the Strategic Advisory Group of Experts 
on Immunization reviewed the non-specific effects of the 
BCG vaccine, and concluded that the evidence was consis-
tent with beneficial NSEs. However, the bulk of evidence 
came from observational studies and they therefore called 
for randomised trials. To our knowledge, this will be the 
first randomised trial assessing the NSEs of BCG and OPV 
vaccination among children in a rural low-income setting. 
The SAGE review did not include OPV, but a recent trial 
from Guinea-Bissau randomised children to BCG only or 
BCG and OPV, and found that OPV was associated with a 
32% reduction in mortality.28 Thus, both BCG and OPV 
may have beneficial NSEs. The results will therefore be very 
important in broadening our understanding of the NSEs 
of BCG and OPV at birth. We will however not be able to 
distinguish the effects of BCG and OPV in this trial.
WHO recommends three home visits after birth, which 
is resource demanding and not implemented in many 
low-income countries. It is not recommended that the 
home visits are utilised for early vaccination. However, 
we hypothesise that a single home visit after birth will 
have major effects on early infant mortality if BCG and 
OPV vaccination are added to the home visit. If BCG and 
OPV provided at a single home visit can reduce early 
infant mortality, this should be included in the WHO 
recommendations. A single home visit with vaccines will 
be easier to implement in a strained health system than 
three home visits within 7 days. In countries, where home 
visits are already in place, vaccines can easily be added to 
reduce early infant mortality.
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